Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Arm Pilot Trial of Adaptive Therapy (AT) With Capecitabine for the Treatment of Metastatic Estrogen Receptor Positive, Hormone Refractory Breast Cancer

NCT06525766 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT06525766
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06525766 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Arm Pilot Trial of Adaptive Therapy (AT) With Capecitabine for the Treatment of Metastatic Estrogen Receptor Positive, Hormone Refractory Breast Cancer
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Recruiting
Start date
October 1, 2025
Completion date
October 15, 2030
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage iv breast cancer ajcc v8, estrogen-receptor-positive breast cancer, metastatic breast cancer, metastatic her2-negative breast carcinoma